Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's RG-6341?
RG-6341 is commercialized by Roche, with a leading Phase II program in Asthma. According to Globaldata, it is involved in...
Risk adjusted net present value: What is the current valuation of Roche's Bepranemab?
Bepranemab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Alzheimer's Disease. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's Autogene cevumeran?
Autogene cevumeran is a mrna vaccine commercialized by Roche, with a leading Phase II program in Triple-Negative Breast Cancer (TNBC)....
Risk adjusted net present value: What is the current valuation of Roche's Vanglusagene ensiparvovec?
Vanglusagene ensiparvovec is a gene therapy commercialized by Roche, with a leading Phase II program in Pompe Disease. According to...
Risk adjusted net present value: What is the current valuation of Roche's Vixarelimab?
Vixarelimab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris). According...
Risk adjusted net present value: What is the current valuation of Roche's Inavolisib?
Inavolisib is a small molecule commercialized by Roche, with a leading Pre-Registration program in Human Epidermal Growth Factor Receptor 2...
Risk adjusted net present value: What is the current valuation of Roche's Ruzotolimod?
Ruzotolimod is a small molecule commercialized by Roche, with a leading Phase II program in Hepatitis B. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's Tiragolumab?
Tiragolumab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Esophageal Squamous Cell Carcinoma (ESCC)....
Risk adjusted net present value: What is the current valuation of Roche's Zilebesiran sodium?
Zilebesiran sodium is an antisense rnai oligonucleotide commercialized by Roche, with a leading Phase II program in Hypertension. According to...
Risk adjusted net present value: What is the current valuation of Roche's Vamikibart?
Vamikibart is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Uveitis. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of Roche's Sefaxersen sodium?
Sefaxersen sodium is an antisense oligonucleotide commercialized by Roche, with a leading Phase III program in IgA Nephropathy (Berger's Disease)....
Risk adjusted net present value: What is the current valuation of Roche's Fenebrutinib?
Fenebrutinib is a small molecule commercialized by Roche, with a leading Phase III program in Relapsing Multiple Sclerosis (RMS). According...
Risk adjusted net present value: What is the current valuation of Roche's RVT-3101?
RVT-3101 is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's Rozlytrek?
Rozlytrek is a small molecule commercialized by Roche, with a leading Phase III program in Squamous Non-Small Cell Lung Cancer....
Risk adjusted net present value: What is the current valuation of Roche's Dirloctocogene Samoparvovec?
Dirloctocogene Samoparvovec is a gene therapy commercialized by Roche, with a leading Phase III program in Hemophilia A (Factor VIII...
Risk adjusted net present value: What is the current valuation of Roche's Astegolimab?
Astegolimab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....
Risk adjusted net present value: What is the current valuation of Roche's Tominersen?
Tominersen is an antisense oligonucleotide commercialized by Roche, with a leading Phase III program in Huntington Disease. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's OpRegen?
OpRegen is a cell therapy commercialized by Roche, with a leading Phase II program in Geographic Atrophy. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's Prasinezumab?
Prasinezumab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Parkinson's Disease. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's Ipatasertib?
Ipatasertib is a small molecule commercialized by Roche, with a leading Phase III program in Human Epidermal Growth Factor Receptor...